Category Archives: Biotech Letter

December 30, 2025

Mad Hedge Biotech and Healthcare Letter December 30, 2025 Fiat Lux   Featured Trade: (BIOTECH’S WATERLOO: THE STOCKS THAT CONQUERED AND THE ONES THAT DIDN’T) (IDXX), (CAH), (HCA), (COR), (MCK), (GILD), (JNJ), (LLY), (ISRG), (WBA), (MRK), (BMY), (MRNA), (BIIB), (ILMN)

Biotech’s Waterloo: The Stocks That Conquered And The Ones That Didn’t

Napoleon once said, “In victory, you deserve champagne. In defeat, you need it.” Healthcare investors popped both in 2025. While the sector at large looked like a casualty of macro shrapnel, a few names marched through the battlefield with earnings like artillery fire – and stock prices to match. The top-line view was grim: the […]

Climbing The Cliff In Reverse

A few months ago, I found myself sipping flat champagne on a Gulfstream out of Aspen, locked in one of those altitude-fueled biotech postmortems. On my left: a hedge fund manager freshly out of his biotech positions after a bruising year. On my right: a dermatologist who moonlights as a GLP‑1 evangelist. Regeneron (REGN) came […]

Champagne or Sham Pain?

You can almost hear the champagne corks popping as Amgen (AMGN) just notched all-time highs and sits comfortably in the portfolios of risk-averse institutions and dividend disciples alike. But in biotech, comfort can be deceptive. Beneath the surface, a patent cliff is forming, a tax storm is brewing, and the pipeline looks more “under renovation” […]